Selcia has successfully completed 14C radiolabelled API projects on behalf of a diverse range of clients for phase 1 human trials, following MHRA GMP Certification in September 2010. In response to a sharp increase in demand for this specialist service, Selcia has invested to double its capacity for handling GMP radiolabelling projects.
“By selecting Selcia for the preparation of their 14C GMP radiolabelled APIs, clients have the widest choice of phase 1 clinics for their human clinical trials.”
Simon Saxby, Selcia's Chief Executive Officer, commented: "This expansion continues our commitment to providing our global client base with the highest quality MHRA certified GMP 14C radiolabelling services, enabling them to conduct human in-vivo studies in compliance with the most rigorous regulatory requirements. As a global leader in 14C radiolabelling, we will continue to invest in highly skilled and experienced scientists and state of the art facilities in order to provide a 'first in class' service to our clients."
Director of Business Development for Radiochemistry, Dave Roberts added: "By selecting Selcia for the preparation of their 14C GMP radiolabelled APIs, clients have the widest choice of phase 1 clinics for their human clinical trials."
Pangolins' genetic makeup linked to increased coronavirus susceptibility